Liu Yuan, Tu Haohua, You Sixian, Chaney Eric J, Marjanovic Marina, Boppart Stephen A
Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Quant Imaging Med Surg. 2019 May;9(5):742-756. doi: 10.21037/qims.2019.04.16.
Label-free molecular profiling, imaging, and analysis are of particular interest in cancer biology for detecting subtle biochemical changes during cancer progression and potentially during cancer treatment. Multimodal, multiphoton imaging that combines diverse molecular contrasts derived from different physical mechanisms can improve our understanding of the tumor microenvironment.
A label-free optical molecular profiling technique has been developed based on penta-modal multiphoton imaging to investigate mammary tumor progression in a pre-clinical rat model. Pulses from a coherent supercontinuum were tailored for two-photon (2PF) and three-photon fluorescence (3PF), second (SHG) and third harmonic generation (THG), and hyperspectral coherent anti-Stokes Raman scattering (CARS)-based imaging. A graphic multiphoton molecular profiling model was constructed to intuitively combine the co-registered quantitative, chemical, functional, and structural tissue information, enabling longitudinal biomolecular analysis.
Over a 9-week period of tumor progression, and even before the formation of solid tumor, we observed lipid-protein transitions, microenvironmental reorganization, and a shift from FAD to NAD(P)H fluorescence, which reflects the reprogramming of cellular metabolism in carcinogenesis.
Multimodal multiphoton imaging reveals and interrelates diverse carcinogenic signatures, identifying biomarkers that could serve as early molecular indicators for breast cancer diagnosis. This quantitative multimodal imaging methodology for molecular profiling of associated cancer biomarkers may have a broader impact in fundamental cancer research and future clinical applications.
无标记分子谱分析、成像及分析在癌症生物学领域备受关注,可用于检测癌症进展过程中以及潜在的癌症治疗过程中的细微生化变化。结合源自不同物理机制的多种分子对比度的多模态多光子成像,能够增进我们对肿瘤微环境的理解。
基于五模态多光子成像开发了一种无标记光学分子谱分析技术,用于研究临床前大鼠模型中的乳腺肿瘤进展。对相干超连续谱的脉冲进行了调整,以用于双光子(2PF)和三光子荧光(3PF)、二次谐波产生(SHG)和三次谐波产生(THG)以及基于高光谱相干反斯托克斯拉曼散射(CARS)的成像。构建了一个图形化多光子分子谱分析模型,以直观地整合经配准的定量、化学、功能和结构组织信息,实现纵向生物分子分析。
在肿瘤进展的9周时间内,甚至在实体瘤形成之前,我们观察到了脂质 - 蛋白质转变、微环境重组以及从FAD到NAD(P)H荧光的转变,这反映了致癌过程中细胞代谢的重编程。
多模态多光子成像揭示并关联了多种致癌特征,识别出可作为乳腺癌诊断早期分子指标的生物标志物。这种用于相关癌症生物标志物分子谱分析的定量多模态成像方法可能会对基础癌症研究和未来临床应用产生更广泛的影响。